Recent Updates
Recently added Catalysts
PRAX Positive Sentiment

Praxis Precision Medicines to Host Conference Call to Announce Topline Results from the RADIANT Trial and Provide Second Quarter 2025 Financial Results

Tuesday, July 29, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Praxis Precision Medicines, Inc. has announced a conference call scheduled for August 4, 2025, to report topline results from its RADIANT trial of vormatrigine and its financial results for the second quarter of 2025. The announcement highlights Praxis's ongoing focus on developing treatments for CNS disorders. Investors can access a live webcast during the event, with a replay available for 90 days on the company's website.
Price reaction · baseline $55.65 (2025-07-28 close) · hit after-hours · clean, no other PRAX news in the window
day 0 close
+0.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Praxis will announce topline results from the promising RADIANT trial.
  • The company is actively developing therapies for CNS disorders.
  • The webcast offers investors direct access to important updates.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+61%
120-day peak, hindsight
Typical move
23.7%
average across 12 past catalysts
Cash runway
~53 mo
Minimal dilution risk
Lead asset
vormatrogine
Phase 3 · Epilepsy, Tonic-Clonic

Full Press Release Details

BOSTON, July 29, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced it will report topline results from the RADIANT trial of vormatrigine and its financial results from the second quarter ended June 30, 2025, before the financial markets open on Monday, August 4, 2025.
The Company will host a live webcast the same morning at 8:30am ET, which can be accessed by visiting this registration link. This live webcast will also be available through the Events & Presentations page of the Investors + Media section of the company’s website. A replay of the webcast will be available on Praxis’ website for 90 days following the event.

Frequently Asked Questions

What trial results will Praxis report on August 4, 2025?

Praxis will report topline results from the RADIANT trial of vormatrigine.

When is the financial results report from Praxis due?

The financial results for the second quarter ended June 30, 2025, are due on August 4.

What time will the webcast be held on August 4, 2025?

The live webcast will take place at 8:30 am ET on August 4, 2025.

How can I access the Praxis webcast?

You can access the webcast via a registration link or on their website's Events page.

How long will the webcast replay be available?

The replay of the webcast will be available for 90 days after the event.

ShareAdd on Google
Tags: PRAX Viatris Investor Conferences Healthcare Praxis Precision Medicines RADIANT trial vormatrigine CNS disorders financial results
Last updated: Jul 29, 2025

Biotech snapshot

Cash runway
$1374M liquidity · $26M/mo burn
~53 mo
Minimal dilution risk
Lead asset
vormatroginePhase 3
Epilepsy, Tonic-Clonic →

Catalyst track record

+61%
best trade around PRAX's most recent catalyst

Peak hindsight return over a 120-day window, across 12 tracked FDA/PDUFA catalysts for PRAX.

See every catalyst's timing & PoA →